EUVIMEDEUVIMED entdecken
Open Access

Acute Pharmacodynamic Effects of Oral Levodopa on Blood Pressure in Parkinson's Disease

Katherine Longardner iD, Cat Liu, Jeremiah Momper iD, Kuldeep Mahato iD, Chochanon Moonla iD, Hamidreza Ghodsi iD, Joseph Wang iD, Irene Litvan iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025-11 · 45 (11) · 721-728

DOI: 10.1002/phar.70066 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2025-10. Verfasst von Katherine Longardner und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, University of California San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Levodopa, Parkinson Disease, Blood Pressure, Carbidopa. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NCATS NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Levodopa decreases blood pressure (BP) in persons with Parkinson's disease (PwP), but no pharmacodynamic studies integrating systemic levodopa concentration measurements have characterized its hypotensive effects. Understanding this relationship is clinically relevant for guiding therapeutic decisions, such as how aggressively to treat hypotension before initiating or increasing levodopa. In this pilot study, we aimed to determine the acute pharmacodynamic effects of oral immediate‐release carbidopa/levodopa on BP in PwP.

Methods

PwP taking chronic oral carbidopa/levodopa with baseline BP ≥ 90/60 mmHg were recruited. Participants withheld antiparkinsonian medications overnight prior to the study visit and received carbidopa/levodopa immediate‐release tablets at time 0. Capillary blood levodopa levels, seated BP measurements, and motor symptom assessments were performed at baseline and repeated every 10 min for 70–100 min. Non‐compartmental pharmacokinetic parameters of levodopa were determined, including the area under the curve up to the last time point (AUC 0 → last ), maximum concentration ( C max ), and time to maximum concentration ( T max ).

Results

Fourteen PwP were enrolled (mean age 69.5 ± 7.6 years, six females). Two participants had orthostatic hypotension at baseline (defined as a sustained drop in systolic BP ≥ 20 mmHg or diastolic BP ≥ 10 mmHg within 3 min of standing), and six were taking antihypertensive medications. Mean arterial pressure (MAP) declined during the study from an average of 105 ± 13.1 mmHg at baseline to a nadir of 84 ± 15.8 mmHg. The maximum MAP drop occurred at 100 min post‐dose. Cumulative levodopa AUC negatively correlated with MAP (Pearson's r = −0.30; p = 0.00036).

Conclusions

Oral levodopa is associated with acute hypotension in PwP, and levodopa exposure is inversely correlated with MAP. These effects should be considered when adjusting levodopa dosing, particularly in patients with hypotension, to improve safety outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LevodopaParkinson DiseaseBlood PressureCarbidopaAntiparkinson AgentsHumansMaleFemaleAgedAdministration, OralPilot ProjectsMiddle AgedDrug Combinations

Stichwörter der Autor:innen

Parkinson's diseaseblood pressurehypotensionlevodopa

Substanzen

LevodopaCarbidopaAntiparkinson Agentscarbidopa, levodopa drug combinationDrug Combinations

Autor:innen und Institutionen

  • Department of Neurosciences, University of California San Diego, La Jolla, California, USA.
  • University of California San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, California, USA.
  • Aiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California San Diego, La Jolla, California, USA.

ORCID-Profile: Katherine Longardner, Jeremiah Momper, Kuldeep Mahato, Chochanon Moonla, Hamidreza Ghodsi, Joseph Wang, Irene Litvan

Förderung

  • NINDS NIH HHS
  • NCATS NIH HHS
  • NIA NIH HHS
  • NIH HHS
  • National Institutes of Health
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Longardner, K., Liu, C., Momper, J., Mahato, K., Moonla, C., Ghodsi, H., Wang, J., & Litvan, I. (2025). Acute Pharmacodynamic Effects of Oral Levodopa on Blood Pressure in Parkinson's Disease. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 45(11), 721-728. https://doi.org/10.1002/phar.70066

Vancouver

Longardner K, Liu C, Momper J, Mahato K, Moonla C, Ghodsi H, et al. Acute Pharmacodynamic Effects of Oral Levodopa on Blood Pressure in Parkinson's Disease. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025;45(11):721-728. doi:10.1002/phar.70066

BibTeX
@article{Longardner2025,
  author = {Longardner, Katherine and Liu, Cat and Momper, Jeremiah and Mahato, Kuldeep and Moonla, Chochanon and Ghodsi, Hamidreza and Wang, Joseph and Litvan, Irene},
  title = {Acute Pharmacodynamic Effects of Oral Levodopa on Blood Pressure in Parkinson's Disease},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2025},
  volume = {45},
  number = {11},
  pages = {721--728},
  doi = {10.1002/phar.70066}
}
Kostenlos starten →